2021 Nov: The first clinical trial of South Korea’s homegrown next-generation chimeric antigen receptor T (CAR-T) cell therapy, which is designed to circumvent immune checkpoint signals, has recently gotten under way.
The Korea Advanced Institute of Science and Technology (KAIST) ngumumkeun Rebo yén uji klinis Fase 1b terapi sél CAR-T na ayeuna dilaksanakeun di Pusat Médis Samsung di Seoul. Uji coba ieu dilakukeun sareng 10 pasien Korea anu kambuh sareng limfoma sél B ageung diffuse refractory. Hak pamasaran pikeun pipa dialihkeun ti universitas ka perusahaan Curocell, anu diadegkeun ku Profesor Kim Chan-hyuk. Curocell tanggung jawab program pamekaran klinis revolusioner immunotherapy.
In addition, a Phase 2 sidang klinis involving seventy participants is going to take place the following year to assess how safe and effective the investigational medication is.
The acronym CAR T, which stands for reséptor antigen chimeric T, is frequently referred to as a miracle cure. This is due to the fact that studies conducted in other countries on terminal blood cancer patients demonstrated that the therapy had a therapeutic effect of more than 80 percent. T cells from a patient are taken from the patient’s blood, genetically enhanced to make them more effective, and then reintroduced to the patient so that they can continue to fight and destroy cancer cells inside the patient’s body.
The research team that was led by Professor Kim of the Department of Biomedical Engineering at the KAIST confirmed an improved anticancer efficacy of CAR-T cells in mice with leukaemia and lymphoma. This was achieved by simultaneously inhibiting programmed cell death protein 1 (PD-1) and T-cell immunoglobulin and ITIM domain (TIGIT), both of which are known to disturb the function of T cells. According to Professor Lee Young-ho, a post-doctoral researcher at KAIST and the first author of the animal model study, this dual blockade of PD-1 and TIGIT is a novel strategy to overcome the immunosuppression of existing CAR-T cells. This strategy was discovered by Prof. Lee Young-ho.
Anjeun panginten hoyong maca: Terapi CAR T-Cell di Koréa
Papanggihan ulikan dibere dina artikel anu diterbitkeun online dina edisi Oktober Terapi Molekul.
